Capricor Therapeutics' HOPE-2 study shows deramiocel improves cardiac function and motor skills in DMD patients with a favorable safety profile.

Capricor Therapeutics reported positive three-year results from its HOPE-2 study on deramiocel, a treatment for Duchenne muscular dystrophy (DMD). The findings showed significant improvements in cardiac function and motor skills in patients, with a favorable safety profile for long-term use. These results were shared at the World Muscle Society Congress, leading to a 9.31% increase in Capricor's stock price on Nasdaq.

October 11, 2024
7 Articles

Further Reading